Asia Pacific Flow Cytometry Market Size, Share, Trends, Growth, and Forecasts 2025 - 2032

The Flow Cytometry Market in Asia Pacific was valued at US$ 1,244.10 million in 2024 and is predicted to reach US$ 2,774.0 million by the end of 2032, expanding at a CAGR of 10.8% from 2025 to 2032.

• Sales of flow cytometers for Immunophenotyping in Asia Pacific accounted for 35.8% share of the market in 2024.
• Asia Pacific accounted for 17.8% share of the global flow cytometry market in 2024.
• As per this latest market research by Persistence Market Research, the market expanded at a CAGR of 4% from 2019 to 2024.

Flow cytometry allows for the rapid multi-parametric examination of single cells in a liquid solution. Lasers are used in flow cytometers to generate scattered and fluorescent light signals, which are detected by photodiodes or photomultiplier tubes.

Flow cytometry is a valuable tool that medical professionals can use to gain insight into the cells within the body. This type of testing can provide information on immune cell counts, cell cycle stages, the presence of cancer cells, and even DNA ligands that bind to specific molecules within cells. For example, by measuring the fluorescence of labeled molecules such as propidium iodide that bind to DNA, flow cytometry can help in the study of these molecular interactions.

Demand for flow cytometers increased significantly in the Asia Pacific region, during the COVID-19 epidemic. The constraints of polymerase chain reaction (PCR) or antibody testing were successfully addressed by COVID-19 testing involving the use of flow cytometers. The outcomes demonstrated greater precision and high throughput capacity. The COVID-19 pandemic has led to an increased demand for flow cytometers, not only for disease diagnostics but also for research and development purposes.

Manufacturers took advantage of this opportunity to develop technologically advanced systems that not only provide higher efficacy but also address the challenges faced by the industry, thereby driving market growth.

• In July 2021, Eurofins Viracor, Inc. launched its Coronavirus SARS-CoV-2 inSIGHT T Cell Immunity testing platform as an example of the advancements made in the field of flow cytometry.

“Growing Demand for High-quality Healthcare Services in ASEAN Economies Fueling Sales of Flow Cytometers”

Flow cytometry has evolved over the last three decades from being a specialized laboratory technique to becoming a routine instrument used by clinical pathologists and immunologists for diagnosing and monitoring patients with cancer and immunological deficiencies. The identification of novel antigen expression patterns has facilitated the detection of malignancies with unique pathophysiology and therapeutic interventions.

The emergence of high-throughput flow cytometry has further enhanced its utility by enabling the use of high-throughput screening (HTS) tests for multiple applications, primarily utilizing multiplexed fluorescence intensity. This technique enables the simultaneous analysis of multiple samples, providing even greater efficiency. Flow cytometry continues to be the preferred platform for monitoring immunological activity and immunotoxicity.

Flow cytometry is considered the most potent single-cell analysis method, and it is increasingly gaining popularity as a technique for tracking clinical studies.

• For instance, in 2019, Beckman Coulter Life Sciences acquired Cytobank. Cytobank is a privately held software as a service (SaaS) company focused on single-cell data analysis. Collaborations will help Beckman Coulter cater to the growing demand for data analysis in clinical research.

Expansion of ASEAN economies has boosted the demand for high-quality healthcare services. One such example is the demand for flow cytometers, which has increased as a result of their increasing use in disease diagnostic research and development.

“High Capital Expenditure Involved in Acquiring & Maintaining Flow Cytometers”

The high cost of advanced flow cytometers that come equipped with technical functionalities is a major factor restraining their sales.

To carry out multiple research projects simultaneously, end users such as clinical laboratories, large research centers, and pharmaceutical companies require numerous flow cytometry machines. The capital expenditures involved in acquiring and maintaining these devices have increased significantly. Despite the growing demand for these instruments, there are some regions where academic institutions and research laboratories face financial constraints and are unable to afford high-functionality devices. In some cases, the cost of these instruments can exceed US$ 100,000.

The overall cost of such instruments is further increased by maintenance fees and other indirect costs. In emerging nations, the installation costs and other associated expenses, particularly in clinical and research applications, can be high, hindering the optimal utilization of flow cytometry equipment.

Why is Australia a Lucrative Market for Manufacturers of Flow Cytometers?

“Increasing Government Spending on Diagnostic R&D Activities in Australia”

Australia accounted for 25.6% share of the Asia Pacific flow cytometry market in 2024 and this trend is expected to continue over the forecast period.

Research and development activities in Australia have been continuously evolving. Scientists and researchers in the country are consistently performing diagnostic tests and conducting breakthrough research to develop innovations.

• According to the Australian Bureau of Statistics in 2024, there has been constant development in research activities in Australia. The Australian government spent US$ 3.6 billion on R&D during the fiscal year 2022 to 2023, which was an increase of US$ 288 million compared to the previous year.
• Private non-profit (PNP) organizations in Australia spent US$ 1.4 billion on R&D during the same fiscal year. In 2024, the Commonwealth government organizations contributed US$ 2.34 billion (65%) of the total government R&D expenditure (GOVERD), while state and territory government organizations contributed US$ 1.3 billion (35%).

What is the Demand Outlook for Flow Cytometers in South Korea?

“Increasing Focus on Enhancing Flow Cytometry Techniques Facilitating High-content Screening”

South Korea held 20.8% share of the cytometry market in Asia Pacific in 2024.

South Korea has been making progress in improving the technology used in flow cytometry, with a variety of applications that allow for high-resolution characterization of individual cells operating in complex cellular networks like the immune system. These advancements include methods to improve multiparameter flow cytometry and reagents to better characterize and analyze immune system-modifying cells.

Advancements in flow cytometry technology have not only enabled research teams to perform improved analysis but have also led to a significant increase in their global distribution. These developments have greatly enhanced the ability to conduct high-throughput, high-content investigations, leading to a comprehensive understanding of the intricate cellular and molecular interactions underlying complex biological systems.

What are the Factors Driving the Sales of Flow Cytometers in Indonesia?

“Rising Incidence of Chronic & Infectious Diseases Pushing Demand for Flow Cytometers”

Indonesia occupied 11.5% share of the Asia Pacific flow cytometry market in 2024.

Indonesia's Ministry of Health (MoH) is responsible for overseeing the registration of medical devices and home healthcare supplies. Products that have obtained approval from the United States FDA and are being sold in the country will be allowed by Indonesian regulators.

Rising incidence of chronic and infectious diseases in the country has led to the growing demand for flow cytometry systems among healthcare practitioners in Indonesia. The real-time analysis of cellular composition, cell signaling, and other immunological pathways offered by these systems has significantly contributed to the rise in demand for flow cytometry technology for diagnostic purposes.

Although Indonesian R&D initiatives have historically been primarily led by the government, they have been poorly organized and short-lived due to the absence of any formal, integrated National Innovation System (NIS) with a controlling structure.

• The establishment of Indonesia's NIS (SINAS) was initiated by the Medium-Term Development Plan 2015 to 2019, which aimed to strengthen Indonesia's capabilities in science, technology, and innovation (STI). The implementation of SINAS is currently ongoing.

Which Flow Cytometry System Accounts for High Sales in Asia Pacific?

“High Demand for Consumables Due to Their Wide Applicability in Cell Screening”

In 2022, the reagents, consumables, and accessories segment held 51.9% share of the market in Asia Pacific.

Consumable products are used in large quantities and are considered disposable components for various assays in flow cytometry. These products are in high demand due to their usage in various applications of flow cytometry, making them a dominant segment. Their high usage is expected to continue, leading to the growth of this segment during the forecast period.

Which Application of Flow Cytometry is Prominent in Asia Pacific?

“Demand for Immunophenotyping Growing Due to its Highly Efficient Detection of Deviations in B-cell Antigen Production”

Immunophenotyping held a market share of 35.8% at the end of 2025.

Flow immunophenotyping, commonly referred to as flow cytometry, is widely used to evaluate the expression of surface and intracellular molecules to distinguish and characterize different cell types. The detection of deviations from the regular pattern of B-cell antigen production is achievable through flow cytometric immunophenotyping.

The research community's increasing attention to these applications has resulted in the development of advanced technologies.

Where is Flow Cytometry Extensively Used?

“Increasing Utilization of Flow Cytometers in Stem Cell Research Contributing to High Product Sales”

Research applications of flow cytometry held a market share of 77.8% in 2025.

Flow cytometry has multiple applications in the research field, and its advanced usage and analysis techniques have boosted its demand for research purposes. Research on stem cells and associated clinical procedures has exhibited tremendous growth.

Clinical research involving flow cytometry applications such as apoptosis, cell function tests, drug resistance testing, immunophenotyping, and counting reticulocytes and reticulated platelets are some of the current areas of interest.

Manufacturers are developing technologically advanced instruments to enhance their global product lines, while domestic players are also actively participating in market consolidation activities. Many key competitors in the market have undertaken strategic efforts such as acquisitions and product launches.

For instance:

• BD has released the BD FACSymphony™ A1 Cell Analyzer, which provides robust flow cytometry capabilities in a small form factor.
• Sysmex Partec has partnered with De Novo Software, a provider of FCS data analysis solutions, to distribute its flagship product, FCS Express 7, to customers in research and industrial markets around the world.

Persistence Market Research has tracked recent developments related to manufacturers of flow cytometers in Asia Pacific, which are available in the full report.

Product:

• Flow Cytometer Systems
  • Traditional Flow Cytometers
    • Cell Sorters
    • Imaging Flow Cytometers
  • Acoustic Focusing Cytometers
  • Next-generation Flow Cytometers
• Reagents, Consumables, & Accessories
• Software
• Services

Application:

• Immunophenotyping
• Cell Sorting
• Cell Cycle Analysis
  • Apoptosis
  • Cell Proliferation Assays
  • Intracellular Calcium Flux
• Detection & Sorting of Exosomes
• Others

Usage:

• Research Use
• Clinical Diagnostics

End User:

• Hospitals
• Diagnostic Laboratories
• Academic & Research Institutes
• Biopharmaceutical Companies

Country:

• South Korea
• Hong Kong
• Taiwan
• Australia
• New Zealand
• Indonesia
• Thailand
• Malaysia
• Vietnam
• Singapore
• Philippines